A systematic review of the effectiveness and cost-effectiveness of palivizumab (SynagisR) in the prevention of respiratory syncytial virus (RSV) infection in infants at high risk of infection

Susan Simpson, Amanda Burls

    Research output: Book/ReportCommissioned report

    Original languageEnglish
    PublisherDepartment of Public Health and Epidemiology, University of Birmingham
    ISBN (Print)0704423219
    Publication statusPublished - 1 Jan 2001

    Cite this